hVIVO (LON:HVO) Trading 4.6% Higher - Time to Buy?

hVIVO plc (LON:HVO - Get Free Report)'s stock price traded up 4.6% during trading on Wednesday . The company traded as high as GBX 12.50 ($0.17) and last traded at GBX 11.77 ($0.16). 5,325,780 shares changed hands during trading, an increase of 46% from the average session volume of 3,635,481 shares. The stock had previously closed at GBX 11.25 ($0.15).

Wall Street Analyst Weigh In

Separately, Shore Capital reiterated a "buy" rating on shares of hVIVO in a report on Friday, May 30th.

hVIVO Stock Performance

The stock has a market cap of £81.37 million, a P/E ratio of 4.74 and a beta of 0.97. The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16. The company has a 50 day simple moving average of GBX 15.69 and a 200-day simple moving average of GBX 17.32.

hVIVO (LON:HVO - Get Free Report) last posted its earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) EPS for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. On average, equities analysts expect that hVIVO plc will post 1.5492958 earnings per share for the current fiscal year.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.